Mount Yale Investment Advisors LLC Grows Position in Danaher Co. (NYSE:DHR)

Mount Yale Investment Advisors LLC grew its stake in Danaher Co. (NYSE:DHR) by 22.3% in the third quarter, HoldingsChannel reports. The institutional investor owned 3,231 shares of the conglomerate’s stock after buying an additional 590 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Danaher were worth $898,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. nVerses Capital LLC acquired a new stake in Danaher during the 2nd quarter worth about $25,000. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher in the second quarter valued at approximately $25,000. Redmont Wealth Advisors LLC acquired a new position in Danaher in the 1st quarter worth approximately $30,000. MFA Wealth Advisors LLC purchased a new position in Danaher during the 2nd quarter worth approximately $51,000. Finally, Financial Connections Group Inc. purchased a new stake in shares of Danaher in the 2nd quarter valued at $51,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Royal Bank of Canada decreased their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday. Stifel Nicolaus upped their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday. Evercore ISI raised their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Wells Fargo & Company assumed coverage on Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target for the company. Finally, The Goldman Sachs Group raised their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $287.28.

Danaher Trading Down 1.0 %

Shares of Danaher stock opened at $245.41 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The firm has a market capitalization of $181.77 billion, a PE ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83. The firm’s 50-day moving average price is $270.00 and its 200 day moving average price is $260.34.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter last year, the business posted $2.02 earnings per share. The business’s quarterly revenue was up 3.1% compared to the same quarter last year. On average, sell-side analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is 18.31%.

Insider Activity

In related news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,059 shares of company stock worth $8,400,897 over the last three months. Insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.